AU2009241514A1 - Novel inhibitors of hepatitis C virus replication - Google Patents

Novel inhibitors of hepatitis C virus replication Download PDF

Info

Publication number
AU2009241514A1
AU2009241514A1 AU2009241514A AU2009241514A AU2009241514A1 AU 2009241514 A1 AU2009241514 A1 AU 2009241514A1 AU 2009241514 A AU2009241514 A AU 2009241514A AU 2009241514 A AU2009241514 A AU 2009241514A AU 2009241514 A1 AU2009241514 A1 AU 2009241514A1
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
ifn
substituted alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009241514A
Other languages
English (en)
Inventor
Leonid Beigelman
Brad O. Buckman
Antitsa Dimitrova Stoycheva
Guangyi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of AU2009241514A1 publication Critical patent/AU2009241514A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/30—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hydrocarbon radicals, substituted by hetero atoms, attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2009241514A 2008-04-15 2009-04-14 Novel inhibitors of hepatitis C virus replication Abandoned AU2009241514A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US4521908P 2008-04-15 2008-04-15
US4521408P 2008-04-15 2008-04-15
US61/045,219 2008-04-15
US61/045,214 2008-04-15
US10985608P 2008-10-30 2008-10-30
US61/109,856 2008-10-30
US11791608P 2008-11-25 2008-11-25
US61/117,916 2008-11-25
US14833709P 2009-01-29 2009-01-29
US61/148,337 2009-01-29
PCT/US2009/040567 WO2009134616A2 (en) 2008-04-15 2009-04-14 Novel inhibitors of hepatitis c virus replication

Publications (1)

Publication Number Publication Date
AU2009241514A1 true AU2009241514A1 (en) 2009-11-05

Family

ID=41078055

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009241514A Abandoned AU2009241514A1 (en) 2008-04-15 2009-04-14 Novel inhibitors of hepatitis C virus replication

Country Status (10)

Country Link
US (1) US20090257979A1 (https=)
EP (1) EP2283002A2 (https=)
JP (1) JP2011516610A (https=)
KR (1) KR20110004439A (https=)
CN (1) CN102026990A (https=)
AU (1) AU2009241514A1 (https=)
BR (1) BRPI0911259A2 (https=)
CA (1) CA2720846A1 (https=)
MX (1) MX2010011307A (https=)
WO (1) WO2009134616A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2725023T3 (es) 2006-10-12 2019-09-18 Galera Labs Llc Métodos para el tratamiento de la mucositis oral
CN102666537A (zh) * 2009-10-20 2012-09-12 艾格尔生物制药股份有限公司 治疗黄病毒科病毒感染的氮杂吲唑
TW201121968A (en) * 2009-11-09 2011-07-01 Intermune Inc Novel inhibitors of hepatitis C virus replication
EP2760874A4 (en) * 2011-09-26 2015-04-08 Galera Therapeutics Llc METHOD FOR THE TREATMENT OF ILLNESSES
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2015018797A2 (en) * 2013-08-05 2015-02-12 Haplogen Gmbh Antiviral compounds
CN105991908B (zh) * 2015-03-16 2019-06-07 迈科威特株式会社 摄像机模块用滤光器转换装置及包含该模块的移动设备
RS60558B1 (sr) 2015-08-11 2020-08-31 Galera Labs Llc Pentaaza makrociklični prstenasti kompleksi koji poseduju oralnu bioraspoloživost
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
KR20180132939A (ko) 2016-05-03 2018-12-12 갈레라 랩스, 엘엘씨 암 치료를 위한 조합 요법
JP7166634B2 (ja) 2016-09-01 2022-11-08 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー ペンタアザ大環状環複合体およびアスコルビン酸化合物による組み合わせ癌療法
IL295620B2 (en) 2017-04-13 2024-01-01 Galera Labs Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025984A (ja) * 1983-07-22 1985-02-08 Tokyo Inst Of Technol ベンゾチアジアジン誘導体の製造方法
JPH0216448A (ja) * 1988-07-04 1990-01-19 Fuji Photo Film Co Ltd 化学物質の分配係数の推算処理方法
EP0876379A1 (en) * 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
US6242443B1 (en) * 1996-06-21 2001-06-05 Novo Nordisk Ais 1,2,4-benzothiadiazine derivatives, their preparation and use
US6156700A (en) * 1997-09-17 2000-12-05 American Cyanmid Company 3-(1,2-Benzisothiazol- and isoxazol-5-yl)-2,4(1H,3H)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3H)-pyrimidinone or thione herbicidal agents
US6943159B1 (en) * 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
US20040162285A1 (en) * 2002-11-01 2004-08-19 Pratt John K. Anti-infective agents
ATE493408T1 (de) * 2002-11-01 2011-01-15 Abbott Lab Antiinfektiöse mittel
US20040097492A1 (en) * 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
US7902203B2 (en) * 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
CA2518465A1 (en) * 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7378414B2 (en) * 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
CA2577528A1 (en) * 2004-08-23 2006-03-02 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
WO2006093801A1 (en) * 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
JP2008540370A (ja) * 2005-05-04 2008-11-20 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式抗ウイルス化合物
NZ573875A (en) * 2006-06-22 2011-11-25 Anadys Pharmaceuticals Inc Pyrro[1,2-b]pyridazinone compounds
JP4199273B2 (ja) * 2006-08-29 2008-12-17 本田技研工業株式会社 車両状態推定装置
TW200840572A (en) * 2006-12-12 2008-10-16 Anadys Pharmaceuticals Inc 5,6-dihydro-1H-pyridin-2-one compounds
US20080188466A1 (en) * 2006-12-21 2008-08-07 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
PT2118074E (pt) * 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US20080227774A1 (en) * 2007-03-15 2008-09-18 Frank Ruebsam 5,5-disubstituted-indolizinone compounds
US7834009B2 (en) * 2007-08-27 2010-11-16 Anadys Pharmaceuticals, Inc. 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds
WO2009152166A1 (en) * 2008-06-10 2009-12-17 Anadys Pharmaceuticals, Inc. [1,2,4]thiadiazine 1,1-dioxide compounds

Also Published As

Publication number Publication date
WO2009134616A3 (en) 2010-03-18
JP2011516610A (ja) 2011-05-26
BRPI0911259A2 (pt) 2015-10-06
KR20110004439A (ko) 2011-01-13
CN102026990A (zh) 2011-04-20
MX2010011307A (es) 2010-11-09
EP2283002A2 (en) 2011-02-16
CA2720846A1 (en) 2009-11-05
WO2009134616A2 (en) 2009-11-05
US20090257979A1 (en) 2009-10-15
WO2009134616A8 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
AU2009241514A1 (en) Novel inhibitors of hepatitis C virus replication
US7781474B2 (en) Inhibitors of hepatitis C virus replication
CA2615666C (en) Novel macrocyclic inhibitors of hepatitis c virus replication
EP1999129B1 (en) Compounds and methods for inhibiting hepatitis c viral replication
AU2008247509A1 (en) Novel macrocyclic inhibitors of hepatitis C virus replication
US20110312996A1 (en) Novel inhibitors of hepatitis c virus replication
AU2008216382A1 (en) Novel inhibitors hepatitis C virus replication
WO2012087976A2 (en) Novel inhibitors of hepatitis c virus replication
EP2185524A1 (en) Novel peptide inhibitors of hepatitis c virus replication
CA2720729A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
TW201116540A (en) Therapeutic antiviral peptides
WO2012054874A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
US20110110890A1 (en) Novel Inhibitors of Hepatitis C Virus Replication
CN101495457A (zh) C型肝炎病毒复制的新颖抑制剂
HK1144683A (en) Novel macrocyclic inhibitors of hepatitis c virus replication
HK1125360B (en) Compounds and methods for inhibiting hepatitis c viral replication

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application